17
Participants
Start Date
December 31, 2006
Primary Completion Date
April 30, 2009
Study Completion Date
April 30, 2009
PX-12
3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
The University of Texas M.D. Anderson Cancer Center, Houston
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale
Arizona Cancer Center, University of Arizona, Tucson
Lead Sponsor
National Cancer Institute (NCI)
NIH
Translational Genomics Research Institute
OTHER
Cascadian Therapeutics Inc.
INDUSTRY